UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014
Operating revenue:
Personalized oncology solutions	$ 453	$ 590	$ 1,245	$ 1,834
Translational oncology solutions	1,376	3,100	4,377	7,258
Total operating revenue	1,829	3,690	5,622	9,092
Costs and operating expenses:
Cost of personalized oncology solutions	674	614	2,190	2,139
Cost of translational oncology solutions	1,301	1,008	3,225	2,585
Research and development	1,093	535	3,757	1,614
Sales and marketing	1,094	821	3,340	2,160
General and administrative	1,086	2,120	3,944	4,476
Total costs and operating expenses	5,248	5,098	16,456	12,974
Loss from operations	(3,419)	(1,408)	(10,834)	(3,882)
Other income (expense):
Change in fair value of warrant liability	621	846	1,401	(1,202)
Other income/(expense), net	(6)	(7)	(3)	(37)
Total other income (expense)	615	839	1,398	(1,239)
Loss before provision for income taxes	(2,804)	(569)	(9,436)	(5,121)
Provision for income taxes	12	5	27	13
Net loss	$ (2,816)	$ (574)	$ (9,463)	$ (5,134)
Net loss per common share outstanding, including redeemable common stock, basic (in dollars per share)	$ (0.04)	$ (0.01)	$ (0.14)	$ (0.08)
Net loss per common share outstanding, including redeemable common stock, diluted (in dollars per share)	$ (0.05)	$ (0.02)	$ (0.16)	$ (0.08)
Weighted average common shares outstanding, including redeemable common stock, basic (in shares)	66,893,364	66,867,114	66,890,929	66,860,792
Weighted average common shares outstanding, including redeemable common stock, diluted (in shares)	67,245,577	66,867,114	67,243,142	66,860,792